Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.32 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241518 | 0.77 | ADRA1A (0.32) | — | |
| SCHEMBL14402875 | 0.72 | RAB9A (0.36) | — | |
| SCHEMBL16974727 | 0.66 | NOS1 (0.41) | — | |
| SCHEMBL239090 | 0.63 | HSD11B1 (0.43) | — | |
| SCHEMBL241519 | 0.63 | CNR1 (0.36) | — | |
| SCHEMBL2365661 | 0.61 | METAP2 (0.43) | — | |
| SCHEMBL27248979 | 0.60 | PARP10 (0.50) | OPRK1KCNH2PARP10PARP15MAP4K4 | |
| SCHEMBL14402861 | 0.60 | EPHX2 (0.37) | — | |
| SCHEMBL11783904 | 0.58 | NPC1 (0.49) | — | |
| SCHEMBL12316318 | 0.58 | PARP10 (0.55) | OPRK1KCNH2PARP10PARP15OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | OPRK1 1610/4885KCNH2 4398/4885PARP10 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.